Skip to main content
IMMGinactive

IMMAGE BIOTHERAPEUTICS CORP.

Biopharma developer (SEC filing verified)·Phase 1·Bethesda, MD, United States·CEO: Mr. Zhi Cong Mou
OncologyRare Disease

IMMG evidence brief

What we can confirm

Market Cap:
$15K

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Market Cap: $15K
BioSniper AIPage evidence connected

Prepared research question

What matters most for IMMG—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

Market Cap

$15K

Cash Runway

—

Lead Asset

—

Next Catalyst

—

Tracking 3 clinical trials for IMMAGE BIOTHERAPEUTICS CORP..

Run IMMAGE BIOTHERAPEUTICS CORP. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available IMMAGE BIOTHERAPEUTICS CORP. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Regulatory

Run my thesis on this company

Financials

Run my thesis on this company

Frequently asked questions

Who is the CEO of IMMAGE BIOTHERAPEUTICS CORP.?

Mr. Zhi Cong Mou is the chief executive officer of IMMAGE BIOTHERAPEUTICS CORP. (IMMG).

Where is IMMAGE BIOTHERAPEUTICS CORP. headquartered?

IMMAGE BIOTHERAPEUTICS CORP. (IMMG) is headquartered in Bethesda, MD, United States.

What therapeutic areas does IMMAGE BIOTHERAPEUTICS CORP. focus on?

IMMAGE BIOTHERAPEUTICS CORP. develops therapies across Oncology, Rare Disease.

923 companies304,846 SEC filings22,720 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.